Last €19.85 EUR
Change Today -0.22 / -1.10%
Volume 22.4K
DBV On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
Xetra
As of 9:33 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

dbv technologies sa (DBV) Snapshot

Open
€20.15
Previous Close
€20.07
Day High
€20.26
Day Low
€19.65
52 Week High
02/19/14 - €23.50
52 Week Low
10/10/13 - €7.66
Market Cap
305.2M
Average Volume 10 Days
12.9K
EPS TTM
€-1.42
Shares Outstanding
15.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DBV TECHNOLOGIES SA (DBV)

Related News

No related news articles were found.

dbv technologies sa (DBV) Related Businessweek News

No Related Businessweek News Found

dbv technologies sa (DBV) Details

DBV Technologies S.A. is engaged in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children. The company provides Diallertest, a non-invasive patch allergy diagnostic for infants, children, or adults for the diagnosis of allergy in cow milk, wheat, and soybean. Its products include Viaskin Peanut, an immunotherapy product for the treatment of patients with peanut allergies; Viaskin Milk, for the treatment of CMPA and eosinophilic esophagitis, as well as food polyallergies; and Viaskin House Dust Mite, a mite desensitization product for the treatment of mite allergy. The company was founded in 2002 and is based in Bagneux, France.

44 Employees
Last Reported Date: 04/16/14
Founded in 2002

dbv technologies sa (DBV) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €389.2K
Compensation as of Fiscal Year 2013.

dbv technologies sa (DBV) Key Developments

DBV Technologies Announces Completion of Enrollment into the CoFAR6 Phase II Trial of Viaskin(R) Peanut for Treatment of Peanut Allergy

DBV Technologies announced that enrollment into the CoFAR6 study, a multi-center, randomized, double-blinded, placebo-controlled phase II clinical trial of Viaskin(R) Peanut for the treatment of peanut allergic children and adults (4 to 25 years of age), has been completed. CoFAR6 study enrollment started on October 18, 2013, with Dr. Hugh Sampson of The Icahn School of Medicine at the Mount Sinai Hospital in New York and Dr. Stacie Jones of the University of Arkansas for Medical Sciences and Arkansas Children's Hospital serving as Co-chairs for the study. Baseline peanut reactivity for patients was established during a double-blind, placebo-controlled food challenge. Clinical efficacy and Immunological responses will be evaluated after 12 months and 30 months of treatment. Safety will be monitored over time. The CoFAR6 study is being conducted by the 5 US-based investigators, who have collectively randomized 75 (ages 4-25 years) with peanut allergy. Patients have been randomized to two doses of a daily Viaskin(R) Peanut, 100ug or 250ug versus placebo on a 1:1:1 ratio.

DBV Technologies S.A. Presents at JMP Securities Healthcare Conference, Jun-25-2014 03:30 PM

DBV Technologies S.A. Presents at JMP Securities Healthcare Conference, Jun-25-2014 03:30 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Charles Ruban, Chief Development Officer, David Schilansky, Chief Financial Officer, Pierre-Henri Benhamou, Co-Founder, Chairman and Chief Executive Officer.

DBV Technologies Presents Robust Preclinical Data at 2014 European Academy of Allergy and Clinical Immunology

DBV Technologies presented robust preclinical data at the 2014 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Copenhagen, Denmark. The data presented provides DBV with a better understanding of Viaskin(R)'s mechanism of action. It also further confirms epicutaneous immunotherapy's ability (EPIT) to modulate over time immune responses due to a powerful T cell (Treg) induction effect in allergic patients. The data presented at EAACI validates the positioning of Viaskin(R) in the treatment of allergic patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DBV:FP €19.85 EUR -0.22

DBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr816.00 DKK -14.00
Allergy Therapeutics PLC 19.25 GBp +0.125
Merck & Co Inc $58.07 USD -0.14
Sanofi €76.69 EUR -0.63
Stallergenes SA €53.70 EUR +2.44
View Industry Companies
 

Industry Analysis

DBV

Industry Average

Valuation DBV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 70.9x
Price/Book 7.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 68.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DBV TECHNOLOGIES SA, please visit www.dbv-technologies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.